Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | Characterizing biological, imaging, and clinical trajectories for precision care in RRMS

Ferhan Qureshi, SVP – Biomarker R&D, Octave Bioscience, Menlo Park, CA, introduces the Octave precision care solution, a multidimensional measurement tool for use in multiple sclerosis (MS) that combines biological, radiographic, and clinical data with sophisticated analytics and AI. The system aims to give better insights into patient trajectories and management strategies on an individual level, as well as shedding new light on disease biology and clinical characteristics. The solution considers the biology of the disease by measuring blood-based biomarkers, magnetic resonance imaging (MRI), which is reviewed by both machine learning and neuroradiologists, and clinical insights through continuous monitoring of patients. The aim is to compile a comprehensive assessment of patients to guide decision making for clinicians. A study is currently being conducted to characterize the proteomic, radiomic, and clinical trajectories of patients with relapsing/remitting MS who are stable on medication (natalizumab, ocrelizumab, or diroximel fumarate). Interim results are expected by the end of 2024. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ferhan Qureshi is an employee of Octave Bioscience.